Dec 3 (Reuters) - Trevi Therapeutics Inc TRVI.O:
TREVI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM HUMAN ABUSE POTENTIAL STUDY OF ORAL NALBUPHINE
TREVI THERAPEUTICS INC: STATISTICALLY SIGNIFICANT LOWER "DRUG LIKING" FOR 81MG AND 162MG DOSES OF ORAL NALBUPHINE VERSUS. BUTORPHANOL
Source text: ID:nPn7QtRw4a
Further company coverage: TRVI.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.